Overview
TB-500 is the name FDA uses for the thymosin beta-4 fragment LKKTETQ, which is distinct from the full-length thymosin beta-4 used in the cited eye-drop trial.[1][2] That identity distinction is central to this guide: evidence about a full-length molecule cannot simply be reassigned to a fragment sharing a familiar product name.[1][2] The relevant studies also need to be separated by route, population, and outcome before any recovery or safety claim is assessed.[1][2] The sections below explain those boundaries, the limitations of the available human evidence, and why research on a related preparation does not validate a commercial injection or stack.
Benefits
The name TB-500 requires clarification before interpreting any study.[1] FDA describes TB-500 as the thymosin beta-4 fragment LKKTETQ and reports that it has not identified human exposure data for that fragment.[1] Full-length thymosin beta-4 has been studied in humans, including investigational eye drops for corneal disease, but that is a different molecule, formulation, target tissue, and route.[2] Those trials cannot validate a vial marketed as TB-500 for tendon repair or whole-body recovery.[1][2] For injury healing with the fragment, direct human clinical benefit remains unestablished in the evidence reviewed here.[1][2]
Safety
For TB-500, FDA reports no identified human exposure data and flags possible immunogenicity associated with aggregation and peptide impurities.[1] Interpret these observations alongside the study population, route, and length of follow-up. A report of an event does not by itself establish causation, while a study that reports few events cannot exclude uncommon or delayed harms. This uncertainty is especially relevant when the product label does not clearly identify the molecule.
Contraindications
FDA's assessment does not establish a safe population for the TB-500 fragment, including pregnancy, breastfeeding or people with serious medical conditions.[1] Eligibility criteria show whom researchers chose to study; they are not a complete assessment of who can safely receive a product. Any conclusion about suitability therefore needs the exact formulation, the person’s health history, and evidence that actually addresses the relevant circumstances.
Interactions
The cited RGN-259 trial tested full-length thymosin beta-4 eye drops, not interactions involving the injected TB-500 fragment.[3] The four-person combination subgroup in the BPC-157 knee report used a product described as thymosin beta-4 and cannot establish the safety of fragment-containing combinations.[4] To evaluate an interaction, the evidence needs to address the substances together and describe the outcome being monitored. Separate studies cannot establish the combined effect, and an unanswered interaction question should remain an uncertainty rather than becoming reassurance.
Forms & dosing
FDA identifies TB-500 as the thymosin beta-4 fragment LKKTETQ.[1] RGN-259 research used full-length thymosin beta-4 in an ophthalmic formulation; its study regimen does not establish an injectable fragment dose.[3] The amount administered is only one part of an intervention: formulation, route, frequency, treatment duration, and monitoring also define what was tested. Keeping those details attached to a result prevents a research schedule from being presented as a validated regimen for a different use.
Results & stopping
In the 18-person trial of full-length thymosin beta-4 eye drops, the prespecified four-week healing comparison was not statistically significant, although a secondary assessment favored treatment two weeks after cessation.[3] These corneal findings do not establish an injury-recovery timeline, durable benefit or stopping schedule for injected TB-500 fragment.[3] Time to a measured response and persistence after treatment ends are separate questions. A meaningful interpretation needs to specify the outcome, when it was assessed, and whether follow-up actually continued after treatment stopped, rather than infer lasting benefit from an early response.
Product quality
FDA's fragment assessment flags aggregation and peptide impurities.[1] Separately, FDA explains that compounded medicines are not reviewed before marketing for safety, effectiveness or quality, and contamination or incorrect strength can cause serious harm.[5] A useful quality assessment needs to connect the tested sample to the actual product and explain what the test can establish. Evidence about identity or composition should remain distinct from evidence that the finished product is effective, suitable for a particular route, or clinically safe.
Status
FDA currently places thymosin beta-4 fragment LKKTETQ, also called TB-500, among withdrawn bulk-substance nominations.[1] Compounding itself does not confer FDA approval on the resulting medicine.[5] Regulatory status needs to be read for the exact substance, finished product, indication, and jurisdiction being discussed. A research publication, a supplier listing, and a regulatory decision answer different questions, so none should be used as a substitute for the others.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
| Evidence type not classifiedNo direct human fragment evidence; indirect full-length ophthalmic trial.[1][2] The name TB-500 requires clarification before interpreting any study.[1] FDA describes TB-500 as the thymosin beta-4 fragment LKKTETQ and reports that it has not identified human exposure data for that fragment.[1] Full-length thymosin beta-4 has been studied in humans, including investigational eye drops for corneal disease, but that is a different molecule, formulation, target tissue, and route.[2] Main limitation: Molecular identity and route prevent extrapolation.[1][2] |
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
Association of serum thymosin β4 with malnutrition-inflammation-atherosclerosis syndrome in peritoneal dialysis patients: a cross-sectional study
Ectopic Expression of Human Thymosin β4 Confers Resistance to Legionella pneumophila during Pulmonary and Systemic Infection in Mice
Expression and localisation of thymosin beta- 4 in the developing human early fetal heart
Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma
Hypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure
Hypoxia/reoxygenation-experienced cancer cell migration and metastasis are regulated by Rap1- and Rac1-GTPase activation via the expression of thymosin beta-4
Identifi cation of Thymosin β 4 as an effector of Hand1-mediated vascular development
Local Photorelease of Caged Thymosin β4 in Locomoting Keratocytes Causes Cell Turning
Modulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio: Possible implication in the regulation of actin dynamics
PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
Recombinant Human Thymosin β4 Attenuates Endotoxemia-Induced ALI and EAE by Suppressing Inflammatory and Oxidative Responses
Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease
Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis
Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function
Serum thymosin β4 levels in patients with hepatitis B virusrelated liver failure
Significance of Thymosin β4 and Implication of PINCH-1-ILK-α-Parvin (PIP) Complex in Human Dilated Cardiomyopathy
Structural basis of actin sequestration by thymosin-β4: implications for WH2 proteins
Synthesis of thymosin β4 by peritoneal macrophages and adherent spleen cells
The Control of Actin Nucleotide Exchange by Thymosin β4 and Profilin. A Potential Regulatory Mechanism for Actin Polymerization in Cells
Thymosin β4-Enhancing Therapeutic Efficacy of Human Adipose-Derived Stem Cells in Mouse Ischemic Hindlimb Model
Thymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis
Thymosin β4 Prevents Oxidative Stress, Inflammation, and Fibrosis in Ethanol- and LPS-Induced Liver Injury in Mice
Thymosin β4 Regulates Focal Adhesion Formation in Human Melanoma Cells and Affects Their Migration and Invasion
Thymosin β4 alleviates renal fibrosis and tubular cell apoptosis through TGF-β pathway inhibition in UUO rat models
Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of human induced-pluripotent stem cell–derived cardiomyocytes in a porcine model of acute myocardial infarction
Thymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells
Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction
Thymosin β4 reverses phenotypic polarization of glial cells and cognitive impairment via negative regulation of NF- κB signaling axis in APP/PS1 mice
Thymosin β4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing
Thymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells
Thymosin-β4 Regulates Motility and Metastasis of Malignant Mouse Fibrosarcoma Cells
Thymosin β4 (Fx peptide) is a potent regulator of actin polymerization in living cells
Thymosin β4: A ubiquitous peptide in rat and mouse tissues
Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids
Thymosin beta‑4 improves endothelial function and reparative potency of diabetic endothelial cells differentiated from patient induced pluripotent stem cells
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
Thymosin β4 Sequesters the Majority of G-actin in Resting Human Polymorphonuclear Leukocytes
FAQs
Is TB-500 the same as thymosin beta-4, and does it heal injuries?
The name TB-500 requires clarification before interpreting any study.[1] FDA describes TB-500 as the thymosin beta-4 fragment LKKTETQ and reports that it has not identified human exposure data for that fragment.[1] Full-length thymosin beta-4 has been studied in humans, including investigational eye drops for corneal disease, but that is a different molecule, formulation, target tissue, and route.[2] Those trials cannot validate a vial marketed as TB-500 for tendon repair or whole-body recovery.[1][2] For injury healing with the fragment, direct human clinical benefit remains unestablished in the evidence reviewed here.[1][2]
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for TB-500.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
9 sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Accessed 2026-10-03)Regulatory assessmentSave study
- 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2023)Primary researchReview status · PendingSave study
- 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2023)Primary researchReview status · PendingSave study
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (2021)Primary researchRead review · DraftSave study
- Understanding the Risks of Compounded Drugs (Accessed 2026-10-03)Regulatory guidanceSave study
- TB-500 vs TB-4
- TB4 vs TB500
- TB4 full sequence vs TB4 frag 17-23 (aka TB-500) for post-surgery recovery?
- Questions on BPC-157 & TB-500 – Dosing, Administration, and Best Sources
Selected public discussions help us choose questions. They are not clinical evidence. Explore discussions
